Healio

Triple-combination therapy exceeds Symbicort Turbohaler for COPD

GlaxoSmithKline and Innoviva’s triple-combination therapy of fluticasone furoate, umeclidinium and vilanterol significantly reduced the amount of exacerbations experienced by patients with chronic ...
PharmiWeb

SYMBICORT (budesonide/formoterol) TURBOHALER 200/6 APPROVED AS FIRST AND ONLY COMBINATION RELIEVER FOR MILD ASTHMA IN THE UK

London, UK, Thursday 23 March 2023 – AstraZeneca today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing ...
Business Wire

GSK presents positive results from phase III FULFIL study of closed triple combination therapy FF/UMEC/VI versus Symbicort® Turbohaler® in COPD at ERS International Congress ...

GSK presents positive results from phase III FULFIL study of closed triple combination therapy FF/UMEC/VI versus Symbicort® Turbohaler® in COPD at ERS International Congress ...
Reuters

AstraZeneca loses Symbicort patent in Europe

LONDON, Oct 18 (Reuters) - AstraZeneca Plc lost a key European patent on its two-in-one asthma drug Symbicort on Thursday but the drugmaker said it did not expect the move to have an immediate impact ...
Pharmabiz

GSK presents positive results from phase III FULFIL study of closed triple combo therapy FF/UMEC/VI versus Symbicort Turbohaler in COPD at ERS congress

GlaxoSmithKline plc and Innoviva, Inc. announced the presentation of further data from the pivotal phase III FULFIL study with investigational closed triple ...